Heparin and deep vein thrombosis

Comparing effects of low dose heparin as intermittent SC injection and continuous IV infusion on the serum biomarkers of thrombosis in critically ill patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201402113449N14

Enrollment

Registered

2014-03-13

Start date

2014-02-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein throbmosis. Formation of thrombosis in the deep veins

Interventions

Intervention 1: Subcutaneous (SC) heparin as 5000 IU TDS. Intervention 2: Intravenous continuous infusion of heparin as 625 IU/hr.

Treatment - Drugs

Subcutaneous (SC) heparin as 5000 IU TDS

Intravenous continuous infusion of heparin as 625 IU/hr

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Critically ill patients with age between 18-65 years old who will be admitted to ICU and have indication for deep vein thrombosis (DVT) prophylaxis Exclusion criteria: Patients who need DVT or pulmonary emboli treatment, have heparin contraindications, autoimmune diseases, history of acute myocardial infarction in last 21 days, and dialysis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Interleukin-10 serum level. Timepoint: Days 0,3,7. Method of measurement: Elisa kit.;P-selectin serum level. Timepoint: Days 0,3,7. Method of measurement: Elisa kit.;Hs-CRP serum level. Timepoint: Days 0,3,7. Method of measurement: Elisa kit.	—

Primary

Measure	Time frame
Incidence of deep vein thrombosis. Timepoint: Daily up to 7 days. Method of measurement: Clinical assessment.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026